^(125)I粒子与免疫检查点抑制剂治疗中晚期肝细胞癌的研究进展  

Research progress in 125I seed and immune checkpoint inhibitor for the treatment of advanced hepatocellular carcinoma

作　　者：赵志远 李培永[2] 张晓福 王宝山[2] 郝国君 申东峰[2] ZHAO Zhiyuan;LI Peiyong;ZHANG Xiaofu;WANG Baoshan;HAO Guojun;SHEN Dongfeng(Graduate School of Shanxi Uninersity of Traditional Chinese Medicine:Deparment of Vascular Intervention,Shanxi Provincial Hospital of Traditional Chinese Medicine Taiyuan,Shanxi Province 030012,China)

机构地区：[1]山西中医药大学研究生院,太原030012 [2]山西省中医院介入血管科

出　　处：《介入放射学杂志》2022年第9期922-926,共5页Journal of Interventional Radiology

摘　　要：中晚期肝细胞癌(HCC)因失去手术机会常采用多手段联合的综合治疗方式。随着^(125)I放射性粒子治疗及免疫检查点抑制剂(ICI)免疫治疗研究的深入,发现^(125)I粒子对于中晚期HCC的肝内病灶、门静脉癌栓、肝外转移病灶等皆有较好的临床疗效。有关PD-1、CTLA-4、TIM-3等ICI治疗中晚期HCC的研究也日趋完善。二者联合在调节肿瘤微环境、更大程度激活免疫效应、降低肿瘤耐药性方面发挥了较大优势,尽管目前有关二者协同应用的报道较少,但其前景仍值得期待。In clinical practice, comprehensive treatment with a variety of means has been commonly employed for the patients with advanced hepatocellular carcinoma(HCC) because these patients have already lost the opportunity of surgical treatment. With the intensive study on the^(125)I radiation seeds therapy and immunotherapy using immune checkpoint inhibitors(ICI), it has been recognized that^(125)I radiation seeds has good clinical effect for intrahepatic HCC foci, portal vein tumor thrombus and extrahepatic metastatic lesions in patients with advanced HCC. Studies on PD-1, CTLA-4, TIM-3 and other immune checkpoint inhibitors for advanced HCC have also been improved day by day. The combination use ofI radiation seeds and ICI has greater advantages in adjusting the tumor microenvironment, activating immune effect, and reducing tumor resistance to drug. Although there are few reports in published literature about the combination use ofI radiation seeds and ICI up now, its application prospects are worth looking forward to.(J Intervent Radiol, 2022, 31: 922-926)

关 键 词：肝细胞癌 125I粒子 免疫检查点抑制剂 

分 类 号：R735.7[医药卫生—肿瘤]